Asset
RODUCITABINE
Processa Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02030067 | phase1_2 | completed | 2013-12-01 | 2019-07-01 | Processa Pharmaceuticals | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies |
| NCT03189914 | phase1_2 | completed | 2017-10-02 | 2019-10-01 | Processa Pharmaceuticals | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer |
FDA applications (0)
This company has no applications containing this asset.